Market research
VLA.PA Valneva SE
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 562M
- P/E ratio
- Not available
- Analyst target
- 6.1929
- Dividend yield
- Not available
- Beta
- 1.35
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0004056851
- Market cap
- 562M
- P/E ratio
- Not available
- Analyst target
- 6.1929
- Dividend yield
- Not available
- Beta
- 1.35
About
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VLA.PA discussion.
5 years, 5 months ago
Valneva SE is currently in a long term uptrend where the price is trading 19.7% above its 200 day moving average.
From a valuation standpoint, the stock is 96.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.2.
Valneva SE's total revenue sank by 75.6% to $11M since the same quarter in the previous year.
Its net income has dropped by 5418.1% to $-37M since the same quarter in the previous year.
Finally, its free cash flow grew by 2276.5% to $49M since the same quarter in the previous year.
Based on the above factors, Valneva SE gets an overall score of 3/5.